Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine

British Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2010, Pages 498-507

  Lal, Ritu ^a   Sukbuntherng, Juthamas ^a   Luo, Wendy ^a   Vicente, Virna ^a   Blumenthal, Robin ^a   Ho, Judy ^a   Cundy, Kenneth C ^a  

^a XenoPort Inc   (United States)

Author keywords

Cimetidine; Drug drug interactions; Gabapentin enacarbil; Naproxen; XP13512 GSK1838262

Indexed keywords

CIMETIDINE; GABAPENTIN; GABAPENTIN ENACARBIL; NAPROXEN; PRODRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; COORDINATION; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG URINE LEVEL; DYSGEUSIA; DYSPEPSIA; EUPHORIA; FATIGUE; FEELING DRUNK; FEELING OF RELAXATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY CLEARANCE; LETHARGY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STEADY STATE; THIRST; TREATMENT DURATION;

ADOLESCENT; ADULT; BIOLOGICAL TRANSPORT; CARBAMATES; CIMETIDINE; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; DYSPEPSIA; FATIGUE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NAPROXEN; PRODRUGS; YOUNG ADULT;

EID: 77950672531     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03616.x     Document Type: Article

References (21)

1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004 311 : 315 323.
2. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004 311 : 324 333.
3. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512/GSK1838262, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008 48 : 1378 1388.
4. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW the XP052 Study Group. A randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS: PIVOT RLS. Neurology 2009 72 : 439 446.
5. Pfizer. Neurontin® (gabapentin) prescribing information. Available at http://www.pfizer.com/files/products/uspi-neurontin.pdf (last accessed 11 November 2008).
6. Choi JS, Jin MJ, Han HK. Role of monocarboxylic acid transporters in the cellular uptake of NSAIDs. J Pharm Pharmacol 2005 57 : 1185 1189.
7. Warren M. Targeting the MCT transporter in drug delivery to increase bioavailability. AAPS Annual Meeting, November 11-15, 2007, San Diego, CA.
8. Gill RK, Saksena S, Alrefai WA, Sarwar Z, Goldstein JL, Carroll RE, Ramaswamy K, Dudeja PK. Expression and membrane localization of MCT isoforms along the length of the human intestine. Am J Physiol Cell Physiol 2005 289 : C846 52.
9. Tamai I, Takanaga H, Maeda H, Sai Y, Ogihara T, Higashida H, Tsuji A. Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 1995 214 : 482 489.
10. +-linked transport of salicylic acid, an NSAID, in the human trophoblast cell line BeWo. Am J Physiol Cell Physiol 2002 282 : C1064 75.
11. Zerangue N. Intestinal absorption. 3rd International Research Conference: Pharma Conference; Transport and Drugs. August 17-21, 2003, Pontresina, Switzerland.
12. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 1999 56 : 1 10.
13. Feng MR, Ouellet D, Li K, Berna K, Ferreira S, Knowlton P, Fountain S, Randinitis E, Haig G, Wesche D. Pharmacokinetic interaction of gabapentin and naproxen in rats and humans. Clin Pharmacol Ther 2003 73 : P50 (abstract).
14. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994 44 : S17 22.
15. Gründemann D, Köster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermüller N, Schömig E. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 1998 273 : 30915 30920. (Pubitemid 28533093)
16. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, Koepsell H. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 2000 279 : F679 87.
17. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998 287 : 800 805.
18. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006 95 : 25 36.
19. US Food and Drug Administration. Guidance for industry drug interaction studies - study design, data analysis, and implications for dosing and labelling. Available at http://www.fda.gov/cder/Guidance/6695dft.htm (last accessed 11 November 2008).
20. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, Brett CM, Burchard EG, Giacomini KM. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008 83 : 416 421.
21. Yabuuchi H, Tamai I, Nezu J-I, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 1999 289 : 768 773.